-
Abstract Number: PB0019
Bambi-deficiency enhances adipose tissue browning, ameliorates dyslipidemia and confers protection against atherosclerosis
-
Abstract Number: OC 01.1
Base and Prime editing of DNA as a new therapeutic option for Hemophilia A
-
Abstract Number: PB0257
Benefits of prolonged anticoagulant treatment in a series of cerebral venous thrombosis in pediatric patients
-
Abstract Number: PB0699
Bevacizumab for refractory hereditary hemorrhagic telangiectasia
-
Abstract Number: PB0542
Bio-equivalence of Potency adjusted approved heparin solutions compared to a newly developed heparin solution.
-
Abstract Number: VPB1284
Biomarker Profiling to Investigate the Molecular and Cellular Pathogenesis of Endothelium in Atrial Fibrillation
-
Abstract Number: PB0082
Biomarkers in COVID-19: Association with disease severity and outcomes
-
Abstract Number: VPB0940
Biomarkers of coagulopathy in patients with different types of acute leukemia
-
Abstract Number: PB1291
Biomarkers of endothelial cell dysfunction in HIV-infected patients
-
Abstract Number: PB0306
Biomarkers of HIV-associated thrombotic thrombocytopaenic purpura (HIV-TTP)
-
Abstract Number: OC 05.4
Biphasic thrombus formation and resolution during a coronavirus infection in the liver
-
Abstract Number: PB0728
Bladder cancer patients have increased NETosis and impaired DNaseI-mediated NET degradation that can be therapeutically restored in vitro
-
Abstract Number: PB0670
Bleed Outcomes in the Moderate and Mild Hemophilia A Population Without Prophylactic Treatment in CHESS II and CHESS PAEDs
-
Abstract Number: PB0181
Bleeding according to FVIII activity in 641 children with non-severe haemophilia – data from the PedNet study group
-
Abstract Number: PB0237
Bleeding assesment in children with Noonan syndrome
-
Abstract Number: PB1237
Bleeding diathesis in a girl with biallelic variants in RASGRP2 gene affecting platelet CalDAG-GEFI function
-
Abstract Number: PO0002
Bleeding disorder in a critically ill patient
-
Abstract Number: OC 70.5
Bleeding in non-severe haemophilia A and B – data from the PedNet study group.
-
Abstract Number: OC 34.1
Bleeding in Patients with Genitourinary Cancer compared to Non-Genitourinary Cancer Treated with Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism
-
Abstract Number: VPB1191
Bleeding of unknown cause or Unclassified Bleeding Disorder : single center experience in west Algeria.
-
Abstract Number: OC 71.3
Bleeding Outcomes for Patients on Anticoagulant and Antiplatelet Therapy
-
Abstract Number: PB0192
Bleeding Rates in Severe Non-inhibitor Haemophilia A Patients Across US, EU4&UK and Japan
-
Abstract Number: PB0499
Bleeding risk assessment in end-stage kidney disease: validation of existing risk scores and evaluation of a machine learning-based approach
-
Abstract Number: PB0056
Bleeding risk of intramuscular injection of COVID-19 vaccines in adult patients with therapeutic anticoagulation
-
Abstract Number: PB0709
Bleeding Story of An Adolescent: Factor VII Deficiency And Repeat Iliopsoas Bleeding
-
Abstract Number: PB0331
Bleeding tendency in thrombocytopenic patients due to impaired defects in primary and secondary hemostasis
-
Abstract Number: PB0908
Bleeding versus thrombosis: Case series on dilemma of VTE management in cancer patients and role of radiotherapy
-
Abstract Number: PB1050
Blockade of K-ras signalling prevents coagulatory phenotype of alternatively activated macrophages.
-
Abstract Number: PB0210
Blood Biodistribution and Vector Shedding of Valoctocogene Roxaparvovec in People with Severe Hemophilia A: Results from the Phase 3 GENEr8-1 Trial
-
Abstract Number: VPB0134
Blood coagulation parameters in hospitalized patients with COVID-19 – data from Regional Center for transfusion medicine Shtip
-
Abstract Number: PB0351
Blood transfusion maintains endothelial cell quiescence – implications in the prevention of stroke in paediatric sickle cell anaemia
-
Abstract Number: VPB0114
BNT162b2 mRNA SARS-CoV-2 vaccination does not cause upregulation of endothelial activation markers or hypercoagulability: A Prospective, Single-Arm, Longitudinal Study.
-
Abstract Number: OC 29.1
Both α- and γ-chain crosslinks mediated by FXIIIa affect fibrin fibre resistance to rupture
-
Abstract Number: OC 03.3
Bradykinin Liberation from High Molecular Weight Kininogen by Plasma Kallikrein on Endothelial Cell Membranes is Modulated by Ambient Concentration of C1 inhibitor and Prolylcarboxypeptidase
-
Abstract Number: OC 48.5
Brain cancers and the risk of intracranial hemorrhage with Direct Oral Anticoagulants (DOACs) versus Low Molecular Weight Heparin (LMWH): A meta-analysis of comparative studies
-
Abstract Number: PB0199
Budget impact of increasing rVIII-SingleChain use in patients in Italy with moderate and severe hemophilia A
-
Abstract Number: PB1110
Buffy-coat-derived megakaryocytes for monoclonal antibody immobilization of platelet antigens (MAIMA) assay
-
Abstract Number: PB0825
Burden of Illness in Patients With von Willebrand Disease Receiving Prophylaxis Versus Potential Prophylaxis-Eligible Patients: A Post-Hoc Analysis of A European Socioeconomic Study
-
Abstract Number: PB0654
Burden of Treatment for Adult and Adolescent People with Haemophilia (PwH): Concept Elicitation Results Supporting the Development of the Hemophilia Treatment Experience Measure (Hemo-TEM)
ISTH 2022 Congress
July 9-13, 2022. London, England, UK.